MARKET

XOMA

XOMA

XOMA Royalty Corporation
NASDAQ
26.61
+0.23
+0.87%
After Hours: 26.51 -0.1 -0.38% 18:39 03/16 EDT
OPEN
26.54
PREV CLOSE
26.38
HIGH
27.39
LOW
26.23
VOLUME
77.42K
TURNOVER
--
52 WEEK HIGH
39.92
52 WEEK LOW
18.35
MARKET CAP
329.51M
P/E (TTM)
35.66
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XOMA last week (0309-0313)?
Weekly Report · 14h ago
XOMA Royalty schedules webcast to discuss fourth-quarter and full-year results
Reuters · 4d ago
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Barchart · 4d ago
Weekly Report: what happened at XOMA last week (0302-0306)?
Weekly Report · 03/09 09:41
XOMA Highlights Royalty Aggregation Strategy in Updated Presentation
TipRanks · 03/02 11:39
XOMA ROYALTY CORP: EXPECTS FY2025 CASH RECEIVED FROM ROYALTIES AND MILESTONES TO BE ABOUT $49 TO $50 MLN
Reuters · 03/02 11:21
Weekly Report: what happened at XOMA last week (0223-0227)?
Weekly Report · 03/02 09:40
What Analysts Are Saying About XOMA Royalty Stock
Benzinga · 02/24 21:00
More
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.